David Spellman
Net worth: - $ as of 30/04/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
LeAnne Zumwalt | F | 65 | 3 years | |
Ronald Frieson | M | 65 | 3 years | |
Willard Dere | M | 70 | 6 years | |
Tracey Vetterick | F | - | 2 years | |
Meredith Bowman | F | - | 2 years | |
Carolyn Rucci | F | - | 3 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jason Amello | M | 55 | 7 years | |
James Ahlers | M | 59 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 17 years |
Raymond T. Keane | M | 65 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 7 years |
Maxine Gowen | M | 66 | 7 years | |
Violetta Cotreau | F | 51 | 2 years | |
Sarah Carmody | F | - | 4 years | |
Elaine Jones | M | 69 | 3 years | |
Sara Nayeem | M | 75 | 6 years | |
Mark Enyedy | M | 60 | 3 years | |
Michael Heffernan | M | 59 | 4 years | |
David Noskowitz | M | - | 2 years | |
James Rosenthal | M | 70 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 3 years |
Donald Bergstrom | M | 52 | 4 years | |
Dirk Huebner | M | 61 | 2 years | |
Dell Faulkingham | M | 51 | - | |
Erin Colgan | F | 43 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | 1 years |
Robert Copeland | M | - | 5 years | |
Kristie Wagner | F | 57 | 8 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 24 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- David Spellman
- Personal Network